Total amount: € 0,00
Indexed/Abstracted in: EMBASE, Scopus, Emerging Sources Citation Index
Online ISSN 1827-1782
De’Santi M. S. 1, Genovese M. 1, Amoroso E. 1, Manto A. 2, Piucci B. 3
1 Neurosurgery Unit “Umberto I” Hospital, Nocera Inferiore, Salerno, Italy
2 Neuroradiology Unit “Umberto I” Hospital, Nocera Inferiore, Salerno, Italy
3 Hospital Service of Pharmacology, “Umberto I” Hospital, Nocera Inferiore, Salerno, Italy
Survival outcomes were observed for 10 patients with glioblastoma multiforme treated with 5-aminolevulinic-acid-(5-ALA)-guided surgery, carmustine wafer implants, and radiation with concomitant and adjuvant temozolomide. Tumour resection was guided by 5-ALA, a fluorescent tumour marker, to facilitate resection and improve outcomes. Carmustine wafer implants were implanted in the tumour cavity at surgery, and patients subsequently received radiation and temozolomide. Median time to progression was 13 months (range: 12-20), and median overall survival was 21 months (16-30). Combining different regimens may be an effective treatment option for patients with glioblastoma multiforme, who generally face a poor prognosis.